Farallon Capital Management LLC Purchases 110,000 Shares of Beta Bionics, Inc. $BBNX

Farallon Capital Management LLC boosted its position in Beta Bionics, Inc. (NASDAQ:BBNX) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,313,920 shares of the company’s stock after purchasing an additional 110,000 shares during the quarter. Farallon Capital Management LLC owned about 9.80% of Beta Bionics worth $85,718,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Beta Bionics in the first quarter worth $95,000. Goldman Sachs Group Inc. purchased a new stake in shares of Beta Bionics in the first quarter worth $715,000. Woodline Partners LP bought a new stake in Beta Bionics during the first quarter valued at $1,530,000. Strs Ohio purchased a new position in Beta Bionics during the first quarter worth about $29,000. Finally, Rhumbline Advisers purchased a new position in Beta Bionics during the first quarter worth about $158,000.

Beta Bionics Stock Up 2.8%

Shares of BBNX stock opened at $10.39 on Monday. The business has a 50-day moving average price of $15.52 and a two-hundred day moving average price of $22.07. Beta Bionics, Inc. has a 12-month low of $8.89 and a 12-month high of $32.71. The firm has a market cap of $461.11 million, a P/E ratio of -5.33 and a beta of 5.59.

Beta Bionics (NASDAQ:BBNX) last announced its quarterly earnings data on Tuesday, February 17th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.12. The firm had revenue of $32.12 million for the quarter. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BBNX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. Wall Street Zen lowered Beta Bionics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Truist Financial decreased their price objective on shares of Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. TD Cowen assumed coverage on shares of Beta Bionics in a research note on Monday, January 26th. They issued a “hold” rating and a $17.00 target price on the stock. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $25.00 target price on shares of Beta Bionics in a research report on Thursday, January 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.20.

Insider Activity at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the sale, the chief financial officer owned 42,614 shares of the company’s stock, valued at $1,258,391.42. This represents a 31.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mike Mensinger sold 2,200 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total transaction of $66,220.00. Following the transaction, the insider owned 80,752 shares in the company, valued at $2,430,635.20. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 34,705 shares of company stock valued at $945,653.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.